Leveraging ADC, RDC, Immuno-oncology, & CDx Clinical Validation to Identify & Progress High-Potential RLT Targets Faster

Validating novel targets remains costly and time-consuming, while a wealth of clinical evidence already exists across ADCs, T-cell engagers, bispecifics, and other targeted therapies.

This workshop will explore how to assess targets validated outside radiopharmaceuticals and determine when there is sufficient evidence to justify progression into an RLT program.

• Mining other modalities for targets: What can we learn from ADCs, T-cell engagers, bispecifics, and other targeted therapies to identify clinically validated targets with potential for RPT?
• Determining what translates: Which target characteristics and clinical data are genuinely transferable, and where do RPT requirements diverge across target accessibility, expression density, internalization, heterogeneity, biodistribution, and normal-tissue uptake?
• Building a cross-modality target-selection framework: Define the evidence required to confidently progress a clinically validated target into RPT, identify the additional RPT-specific validation needed and establish

Speakers:

Keene Wei

Chief Executive Officer

Vitsgen Therapeutics, Inc.

Quaovi Sodji

Assistant Professor

University of Wisconsin-Madison

Vamsi Parimi

Medical Director, ADC Biomarkers

Pfizer (Former)